Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial.
- DOI
- 10.1016/s2665-9913(26)00252-3
- Published
- 2026 Sep 16
- Container
- The Lancet. Rheumatology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2665-9913-26-00252-3,
title = {Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial.},
author = {Goebel A and Meisner P and Rydevik G and Vugler A and Ioannou Y and Tankisheva E and Ewen C and Lambert J and Shaw S and Matthews I},
year = {2026},
journal = {The Lancet. Rheumatology},
doi = {10.1016/s2665-9913(26)00252-3},
url = {https://doi.org/10.1016/s2665-9913(26)00252-3}
}RIS
TY - JOUR TI - Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial. AU - Goebel A AU - Meisner P AU - Rydevik G AU - Vugler A AU - Ioannou Y AU - Tankisheva E AU - Ewen C AU - Lambert J AU - Shaw S AU - Matthews I PY - 2026 JO - The Lancet. Rheumatology DO - 10.1016/s2665-9913(26)00252-3 UR - https://doi.org/10.1016/s2665-9913(26)00252-3 ER -
APA
A, G., P, M., G, R., A, V., Y, I., E, T., C, E., J, L., S, S., & I, M. (2026). Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial.. The Lancet. Rheumatology. https://doi.org/10.1016/s2665-9913(26)00252-3
Source records
- pubmed · retrieved 2026-09-26T13:58:29.009Z